Anti-CD2AP/ CMS monoclonal antibody

Anti-CD2AP/ CMS antibody for FACS & in-vivo assay

Target products collectionGo to CD2AP/CD2AP products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2042-Ab-1/ GM-Tg-hg-MP2042-Ab-2Anti-Human CD2AP monoclonal antibodyHuman
GM-Tg-rg-MP2042-Ab-1/ GM-Tg-rg-MP2042-Ab-2Anti-Rat CD2AP monoclonal antibodyRat
GM-Tg-mg-MP2042-Ab-1/ GM-Tg-mg-MP2042-Ab-2Anti-Mouse CD2AP monoclonal antibodyMouse
GM-Tg-cynog-MP2042-Ab-1/ GM-Tg-cynog-MP2042-Ab-2Anti-Cynomolgus/ Rhesus macaque CD2AP monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2042-Ab-1/ GM-Tg-felg-MP2042-Ab-2Anti-Feline CD2AP monoclonal antibodyFeline
GM-Tg-cang-MP2042-Ab-1/ GM-Tg-cang-MP2042-Ab-2Anti-Canine CD2AP monoclonal antibodyCanine
GM-Tg-bovg-MP2042-Ab-1/ GM-Tg-bovg-MP2042-Ab-2Anti-Bovine CD2AP monoclonal antibodyBovine
GM-Tg-equg-MP2042-Ab-1/ GM-Tg-equg-MP2042-Ab-2Anti-Equine CD2AP monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2042-Ab-1/ GM-Tg-hg-MP2042-Ab-2; GM-Tg-rg-MP2042-Ab-1/ GM-Tg-rg-MP2042-Ab-2;
GM-Tg-mg-MP2042-Ab-1/ GM-Tg-mg-MP2042-Ab-2; GM-Tg-cynog-MP2042-Ab-1/ GM-Tg-cynog-MP2042-Ab-2;
GM-Tg-felg-MP2042-Ab-1/ GM-Tg-felg-MP2042-Ab-2; GM-Tg-cang-MP2042-Ab-1/ GM-Tg-cang-MP2042-Ab-2;
GM-Tg-bovg-MP2042-Ab-1/ GM-Tg-bovg-MP2042-Ab-2; GM-Tg-equg-MP2042-Ab-1/ GM-Tg-equg-MP2042-Ab-2
Products NameAnti-CD2AP monoclonal antibody
Formatmab
Target NameCD2AP
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CD2AP benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CD2AP/ CMS VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2042
    Target NameCD2AP
    Gene ID23607,12488,316258,705221,474928,101091623,533188,100068514
    Gene Symbol and SynonymsCD2AP,CMS,METS-1,Mets1
    Uniprot AccessionQ9Y5K6,F1LRS8
    Uniprot Entry NameCD2AP_HUMAN,CD2AP_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseProstate Cancer
    Gene EnsemblENSG00000198087
    Target ClassificationN/A

    The target: CD2AP, gene name: CD2AP, also named as CMS. This gene encodes a scaffolding molecule that regulates the actin cytoskeleton. The protein directly interacts with filamentous actin and a variety of cell membrane proteins through multiple actin binding sites, SH3 domains, and a proline-rich region containing binding sites for SH3 domains. The cytoplasmic protein localizes to membrane ruffles, lipid rafts, and the leading edges of cells. It is implicated in dynamic actin remodeling and membrane trafficking that occurs during receptor endocytosis and cytokinesis. Haploinsufficiency of this gene is implicated in susceptibility to glomerular disease. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.